Cargando…

Response to Misused and Misleading: 100% Response Rate to Galcanezumab in Patients With Episodic Migraine

Detalles Bibliográficos
Autores principales:	Rosen, Noah, Pearlman, Eric, Ruff, Dustin, Day, Kathleen, Nagy, Abraham Jim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Comments, Observations, and Rebuttals
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6594135/ https://www.ncbi.nlm.nih.gov/pubmed/30973202 http://dx.doi.org/10.1111/head.13514

Ejemplares similares

100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double‐Blind, Placebo‐Controlled EVOLVE‐1 and EVOLVE‐2 Studies
por: Rosen, Noah, et al.
Publicado: (2018)

Neointima development in externally stented saphenous vein grafts. Progress in medicine is good for the patient: why not use total arterial revascularization?: Response to the Letter to the Editor: Neointima development in externally stented saphenous vein grafts. External stents are bad for the patient: why not use an undamaged saphenous vein for coronary artery bypass graft?
por: Krejca, Michał, et al.
Publicado: (2017)

The role of calcium and predation on plate morph evolution in the three-spined stickleback (Gasterosteus aculeatus)
por: Smith, Carl, et al.
Publicado: (2014)

Independence from industry cannot be compromised
por: McMahon, Graham T.
Publicado: (2017)

Industry - from sponsor to provider?
por: Griebenow, Reinhard
Publicado: (2017)

Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine
por: Ament, Michael, et al.
Publicado: (2021)

Correction to: Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine
por: Ament, Michael, et al.
Publicado: (2021)

Analysis of Initial Nonresponders to Galcanezumab in Patients With Episodic or Chronic Migraine: Results From the EVOLVE‐1, EVOLVE‐2, and REGAIN Randomized, Double‐Blind, Placebo‐Controlled Studies
por: Nichols, Russell, et al.
Publicado: (2018)

Early Onset and Maintenance Effect of Galcanezumab in Japanese Patients with Episodic Migraine
por: Igarashi, Hisaka, et al.
Publicado: (2021)

Assessment of immunogenicity from galcanezumab phase 3 trials in patients with episodic or chronic migraine
por: Martinez, James M, et al.
Publicado: (2020)

Galcanezumab for migraine
Publicado: (2020)

Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis
por: Goadsby, Peter J, et al.
Publicado: (2019)

Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With Migraine
por: Ford, Janet H., et al.
Publicado: (2020)

Migraine Disability Improvement during Treatment with Galcanezumab in Patients with Chronic and High Frequency Episodic Migraine
por: di Cola, Francesca Schiano, et al.
Publicado: (2023)

Aortic and Coronary Ostial Stenoses
Publicado: (2001)

Pathological Evidence of Coronary Arterial and Heart Disease before 1768
Publicado: (2001)

Negative Evidence
Publicado: (2001)

Coronary Heart Disease Frequency in the Absence of Traditional Risk Factors
Publicado: (2001)

Early Descriptions of Possible Angina Pectoris
Publicado: (2001)

Positive response to galcanezumab following treatment failure to onabotulinumtoxinA in patients with migraine: post hoc analyses of three randomized double‐blind studies
por: Ailani, J., et al.
Publicado: (2019)

Galcanezumab Provides Consistent Efficacy Throughout the Dosing Interval Among Patients with Episodic and Chronic Migraine: A Post Hoc Analysis
por: Pozo-Rosich, Patricia, et al.
Publicado: (2021)

Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Analysis of the EVOLVE Studies
por: Detke, Holland C., et al.
Publicado: (2019)

Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative Review
por: Martin, Vincent, et al.
Publicado: (2020)

Efficacy of galcanezumab in patients with episodic migraine and a history of preventive treatment failure: results from two global randomized clinical trials
por: Ruff, D. D., et al.
Publicado: (2019)

Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2)
por: Silberstein, Stephen D., et al.
Publicado: (2019)

Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study
por: Hu, Bo, et al.
Publicado: (2022)

Predictors of galcanezumab response in a real-world study of Korean patients with migraine
por: Kim, Seung Ae, et al.
Publicado: (2023)

Flawed research methods result in misleading conclusions
por: McLean, Rachael M., et al.
Publicado: (2023)

Correction to: Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2)
por: Silberstein, Stephen D., et al.
Publicado: (2019)

An Evidence-Based Review of Galcanezumab for the Treatment of Migraine
por: Urits, Ivan, et al.
Publicado: (2020)

Photophobia and migraine outcome during treatment with galcanezumab
por: Schiano di Cola, Francesca, et al.
Publicado: (2023)

Reducing Episodic Cluster Headaches: Focus on Galcanezumab
por: Pellesi, Lanfranco, et al.
Publicado: (2020)

Galcanezumab Effects on Migraine Severity and Symptoms in Japanese Patients with Episodic Migraine: Secondary Analysis of a Phase 2 Randomized Trial
por: Igarashi, Hisaka, et al.
Publicado: (2022)

Treatment Satisfaction of Galcanezumab in Japanese Patients with Episodic Migraine: A Phase 2 Randomized Controlled Study
por: Tatsuoka, Yoshihisa, et al.
Publicado: (2021)

Galcanezumab in patients with episodic migraine: results from the open-label period of the phase 3 PERSIST study
por: Zhou, Jiying, et al.
Publicado: (2023)

One-Time Use of Galcanezumab or Fremanezumab for Migraine Prevention
por: Katsuki, Masahito, et al.
Publicado: (2023)

The Role of Galcanezumab in Migraine Prevention: Existing Data and Future Directions
por: Gklinos, Panagiotis, et al.
Publicado: (2021)

Onset, Maintenance, and Cessation of Effect of Galcanezumab for Prevention of Migraine: A Narrative Review of Three Randomized Placebo-Controlled Trials
por: Kuruppu, Dulanji K., et al.
Publicado: (2021)

Central effects of galcanezumab in migraine: a pilot study on Steady State Visual Evoked Potentials and occipital hemodynamic response in migraine patients
por: de Tommaso, Marina, et al.
Publicado: (2022)

Two randomized migraine studies of galcanezumab: Effects on patient functioning and disability
por: Ford, Janet H., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1dql5trqms5f6i6hao7cdfh2v9